Completed PHASE2 NCT00245362
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Sponsor: Cell Genesys
Interventions
CG 8020 and CG 2505
Updated 4 times since 2017 Last updated: Oct 27, 2005 Started: Jun 30, 2002 Completion: Jun 30, 2004
A PHASE2 clinical study on Metastatic Pancreatic Cancer and Nonresectable Pancreatic Cancer, this trial is completed. The trial is conducted by Cell Genesys and has accumulated 4 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE2
First recorded
Jun 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Cell Genesys
Data source: Cell Genesys
For direct contact, visit the study record on ClinicalTrials.gov .